Drawing for POWDERHALE

USPTO serial 87040256

POWDERHALE

Reviewed by CopyMark Law Group

Reg. 5239476Status 710
Filing date
Status date
Registration date
Jul 11, 2017
Examiner
VOHRA, SANJEEV KUMAR
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with POWDERHALE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark Harrison

MARK HARRISON VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043-9998UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system; pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for the alleviation or prevention of pain or inflammation; inhalers filled with powders for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical preparations, namely, powders for asthma inhalers; pharmaceutical preparations, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for erectile dysfunction; pharmaceutical and veterinary preparations for chronic obstructive pulmonary disease; pharmaceutical and veterinary preparations for premature ejaculation; pharmaceutical and veterinary preparations for cystic fibrosis; pharmaceutical and veterinary preparations for female sexual dysfunction; medicaments for migraine; pharmaceutical and veterinary preparations for asthmaSECTION 8 - CANCELLED—
010Inhalers for medical purposes, sold empty; metered dose inhalers for medical purposes, sold empty; active dry powder inhalers for medical purposes, sold empty; passive dry powder inhalers for medical purposes, sold empty; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goodsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 26, 2024C8..CANCELLED SEC. 8 (6-YR)—
Jul 11, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 11, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 25, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 25, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 5, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 18, 2017ATRVATTORNEY REVIEW COMPLETED—
Feb 24, 2017OTHECASE RETURNED TO EXAMINATION—
Feb 24, 2017IUCNNOTICE OF ALLOWANCE CANCELLED—
Feb 22, 2017PCBGPETITION TO DIRECTOR - CHANGE BASIS - GRANTED—
Feb 16, 2017ERTITEAS RESPONSE TO PETITION INQUIRY LETTER—
Feb 13, 2017PILMPETITION INQUIRY LETTER ISSUED—
Feb 8, 2017APETASSIGNED TO PETITION STAFF—
Feb 8, 201744EP44(e) PETITION - RECEIVED—
Jan 21, 2017AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 21, 2016EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Dec 13, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 18, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 18, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 28, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 12, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 1, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 1, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Sep 1, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 1, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 1, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 31, 2016DOCKASSIGNED TO EXAMINER—
Jul 14, 2016AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jul 8, 2016ALIEASSIGNED TO LIE—
Jul 1, 2016PARITEAS VOLUNTARY AMENDMENT RECEIVED—
May 24, 2016MPMKNOTICE OF PSEUDO MARK E-MAILED—
May 23, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 20, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance